Unbiased Analysis of Today's Healthcare Issues
Seven CEOs from large pharmaceutical firms were brought before Congress today. And they got an earful from both Demogratic and Republican Congressmen. The executives were critique for selling too many opioids. They were critiqued for legal manuevers to extend brand name drugs’ patent life. But most of all, they were critiqued for high drug prices.…
IVI will be hosting two webinars introducing our new open-source value model in non-small cell lung cancer. Devin Incerti and Jeroen Jansen will lead the webinar tomorrow. Modernizing Models for Value Assessment: A Detailed Discussion of the Open-Source IVI-NSCLC Model Date: February 27, 2019 at 2:30 PM EST / 11:30 AM PST Content: In-depth discussion…
So you want to compare two treatments–for instance Treatment A and Treatment B–in order to see which one has largest impact on health outcomes. Sure you could do a randomized controlled trial, but let’s say you don’t have the funding for that. You could use real world data to conduct just such an analysis. Let’s…
Let’s say you go to an in-network provider. If you have fairly generous health insurance (i.e., not a high-deductible health plan), one would expect the cost sharing to be fairly modest. That is not always the case. You may be charged out-of-network cost sharing rates through no fault of your own. In a report by…
Medication adherence and physician quality. Drug price iceberg. Trust, but verify. Fewer hospitals offering substance use disorder services. Build your own Medicare for all.
That is the conclusion from a Health Affairs article by Sisko et al. (2019). National health expenditures are projected to grow at an average annual rate of 5.5 percent for 2018–27 and represent 19.4 percent of gross domestic product in 2027. Following a ten-year period largely influenced by the Great Recession and major health reform, national health spending growth…
Devin Incerti does not blog much; only about 7 times in 4 years. When he does, however, it’s worth paying attention. For instance, he has put together a super helpful blog post describing how to do probabilistic sensitivity analysis (PSA) in R. A key feature of any PSA is determining the distribution from which one…
The answer appears to be ‘yes’ according to a survey by Mahendraratnam et al. (2019). After surveying subject matter experts that were senior representatives from payer organizations and pharmaceutical manufacturers on value-based pricing arrangements (VBA), they found: More than 70% of VBAs implemented between 2014 and 2017 were not publicly disclosed. Furthermore, although consideration of…
Regulation and quality: home health edition. NICE + CADTH = consultants? The start of price transparency? Gottlieb: Use of RWD, machine learning in clinical trials Experiencing patient experience.
Measuring treatment value is difficult. Costs are relatively easier to measure but benefits are often more difficult, particularly impact on caregiver burden, productivity, quality of life and other factors. Not only that, but the “benefits” that accrue to a person may vary by individual. Some individuals may prefer treatments that are more effective, but with…